Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.86)
# 3,112
Out of 4,931 analysts
41
Total ratings
47.37%
Success rate
0.7%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $111.35 | +34.71% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $26.61 | +200.64% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $10.65 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $74.07 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $8.46 | +41.93% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $47.43 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $48.76 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $5.46 | +541.03% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $115.92 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $672.35 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $37.58 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $111.35
Upside: +34.71%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $26.61
Upside: +200.64%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $10.65
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $74.07
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $8.46
Upside: +41.93%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $47.43
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $48.76
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $5.46
Upside: +541.03%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $115.92
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $672.35
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $37.58
Upside: -